SK8599A3 - Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal - Google Patents

Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal Download PDF

Info

Publication number
SK8599A3
SK8599A3 SK85-99A SK8599A SK8599A3 SK 8599 A3 SK8599 A3 SK 8599A3 SK 8599 A SK8599 A SK 8599A SK 8599 A3 SK8599 A3 SK 8599A3
Authority
SK
Slovakia
Prior art keywords
carbon atoms
alkylene
group
formula
compound
Prior art date
Application number
SK85-99A
Other languages
English (en)
Slovak (sk)
Inventor
Jeffrey M Dener
Elaine Yee-Lin Kuo
Ken D Rice
Vivian R Wang
Wendy B Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of SK8599A3 publication Critical patent/SK8599A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
SK85-99A 1996-07-30 1997-07-30 Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal SK8599A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (1)

Publication Number Publication Date
SK8599A3 true SK8599A3 (en) 2000-03-13

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
SK85-99A SK8599A3 (en) 1996-07-30 1997-07-30 Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal

Country Status (17)

Country Link
EP (1) EP0934293A1 (cs)
JP (1) JP2001509787A (cs)
KR (1) KR20000029679A (cs)
CN (1) CN1073103C (cs)
AU (1) AU733621B2 (cs)
CA (1) CA2262542A1 (cs)
CZ (1) CZ29799A3 (cs)
EE (1) EE9900036A (cs)
FI (1) FI990171A7 (cs)
HU (1) HUP0003267A3 (cs)
LV (1) LV12291B (cs)
NO (1) NO990433L (cs)
NZ (1) NZ333713A (cs)
PL (1) PL331465A1 (cs)
SI (1) SI9720047A (cs)
SK (1) SK8599A3 (cs)
WO (1) WO1998004537A1 (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
ES2233025T3 (es) * 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
JP2003524598A (ja) * 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト 新規ピラノセン
EP1208089B1 (en) 1999-08-10 2004-10-13 ALTANA Pharma AG Diazocin-dione derivatives and their use as tryptase inhibitors
US6960588B1 (en) 1999-09-14 2005-11-01 Altana Pharma Ag Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2222259T3 (es) * 1999-12-20 2005-02-01 Altana Pharma Ag Inhibidores de triptasa.
CA2392127A1 (en) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
EP1358182B1 (en) * 2001-01-31 2004-08-11 ALTANA Pharma AG Diazocine derivatives and their use as tryptase inhibitors
WO2002066430A1 (en) 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
JP2004518735A (ja) 2001-02-21 2004-06-24 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼインヒビター
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100347A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6962941B2 (en) 2001-06-19 2005-11-08 Altana Pharma Ag Tryptase inhibitors
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
MX2011006353A (es) 2008-12-19 2011-07-13 Merz Pharma Gmbh & Co Kgaa Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
WO2018207950A1 (ja) * 2017-05-12 2018-11-15 横山　茂之 クラスａ ｇｐｃｒ結合性化合物改変体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
SK282537B6 (sk) * 1993-03-12 2002-10-08 Axys Pharmaceuticals, Inc. Inhibítor tryptázy alebo jeho farmaceuticky prijateľná soľ, farmaceutický prostriedok s jeho obsahom a jeho použitie
US5656660A (en) * 1994-06-01 1997-08-12 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
SK37997A3 (en) * 1994-09-23 1998-12-02 Arris Pharm Corp Compositions and methods for treating mast-cell inflammatory condition
JPH11503417A (ja) * 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション 可逆的プロテアーゼインヒビター
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
FI990171L (fi) 1999-03-23
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
AU733621B2 (en) 2001-05-17
FI990171A7 (fi) 1999-03-23
CN1073103C (zh) 2001-10-17
CA2262542A1 (en) 1998-02-05
FI990171A0 (fi) 1999-01-29
HUP0003267A3 (en) 2002-02-28
CN1226892A (zh) 1999-08-25
EE9900036A (et) 1999-08-16
WO1998004537A1 (en) 1998-02-05
SI9720047A (sl) 1999-08-31
JP2001509787A (ja) 2001-07-24
NO990433L (no) 1999-03-25
NO990433D0 (no) 1999-01-29
KR20000029679A (ko) 2000-05-25
NZ333713A (en) 2000-12-22
EP0934293A1 (en) 1999-08-11
PL331465A1 (en) 1999-07-19
HUP0003267A2 (hu) 2001-06-28
AU3967097A (en) 1998-02-20
LV12291B (en) 2000-04-20

Similar Documents

Publication Publication Date Title
SK8599A3 (en) Disubstituted cyclic compound, process for its preparation, pharmaceutical composition and method of the treatment of an animal
AU721247B2 (en) Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
CZ87097A3 (en) Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells
SK17312001A3 (sk) Inhibítory metaloproteázy
WO2000027826A1 (de) Neue pyrimidine, deren herstellung und verwendung
JP2002502850A (ja) トリプターゼ阻害物質
JP2003509417A (ja) トリプターゼインヒビター
US7482468B2 (en) Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
EP1115731A2 (de) Neue pyranosen
AU777026B2 (en) Novel tryptase inhibitors
US7015325B2 (en) Tryptase inhibitors
DE102007010815B3 (de) Meta-substituierte Phenylsulfonylamide sekundärer Aminosäureamide, ihre Herstellung und Verwendung als Hemmstoffe der Matriptase
US6815557B2 (en) Tryptase inhibitors
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
NZ506614A (en) Compounds for treating diseases associated with tryptase activity
DE60217076T2 (de) Tryptaseinhibitoren
AU2002253035A1 (en) Tryptase inhibitors
LV12458B (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES